title: [Effect of concomitant use of dental drug on the properties of recombinant human basic fibroblast growth factor formulation for periodontal disease].
abstract: We have discussed the essential property for periodontal disease medication using protein, such as recombinant human basic fibroblast growth factor (rhbFGF). In our previous study, the criteria of thickener for the medication, viscosity, flowability etc., were set. The aim of this study was to evaluate the physical and chemical effect of concomitant use of general dental drug or device on thickener properties for the clinical use of viscous rhbFGF formulation. Viscous formulation was prepared with six cellulose derivatives, two types hydroxy propyl cellulose (HPC), three types hydroxy ethyl cellulose (HEC) and methyl cellulose (MC). Antibiotic ointment, local anesthetic, bone graft substitute, agent for gargle and mouthwashes, were chosen as general dental drug and device. These drugs and device were mixed with the viscous formulations and the change of viscosity and flowability, the remaining ratio of rhbFGF were evaluated. When the various thickener solutions were mixed with the liquid drugs, viscosity and flowability did not changed much. However, in the case of MC solution, viscous property declined greatly when MC solution was mixed with cationic surfactant for gargle. The flowabilities of thickener solutions were declined with insoluble bone graft. The stabilities of rhbFGF in thickener solutions were no problem for 24 hours even in the case of mixing with dental drug or device. Our findings suggested that the viscous rhbFGF formulations prepared in this research were not substantially affected by the concomitant use of dental drug or device, especially the formulation with HPC or HEC was useful.
authors.affiliation: Drug Formulation Department, Central Research Laboratories, Kaken Pharmaceutical Co. Ltd., Fujieda, Shizuoka, Japan. sato_yasuhiko@kaken.co.jp
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Sato
authors.forename: Takuma
authors.initials: T
authors.lastname: Oba
authors.forename: Kazumi
authors.initials: K
authors.lastname: Danjo
mesh_terms: D000277:Adjuvants, Pharmaceutic; D002482:Cellulose / Q000031:analogs & derivatives; D055598:Chemical Phenomena / Q000187:drug effects*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D016222:Fibroblast Growth Factor 2 / Q000737:chemistry*; D053210:Pharmaceutical Preparations, Dental / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000737:chemistry*; D014783:Viscosity / Q000187:drug effects
chemical_list: D000277:Adjuvants, Pharmaceutic; C100666:KCB-1 protein, recombinant; D053210:Pharmaceutical Preparations, Dental; D011994:Recombinant Proteins; C531250:hydroxyethyl cellulose ethoxylate; D016222:Fibroblast Growth Factor 2; D002482:Cellulose; C008079:hydroxypropylcellulose